Business
Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March
Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum® platform, today outlined its participation in a series of major international industry events taking place in March 2026.These high-profile meetings will provide Defence with multiple opportunities to advance strategic partnerships, strengthen...
About this update from Defence Therapeutics Inc Class A
[{"type":"text","content":"Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum® platform, today outlined its participation in a series of major international industry events taking place in March 2026.","length":395,"tagName":"p"},{"type":"text","content":"These high-profile meetings will provide Defence with multiple opportunities to advance strategic partnerships, strengthen its global network, and further position Accum® as a differentiated intracellular delivery technology for antibody-drug conjugates (ADCs), radiopharmaceutical conjugates (RDCs), and other complex biologics.","length":329,"tagName":"p"},{"type":"text","content":"BIO-Europe Spring: Primary Focus on Strategic Partnerships","length":58,"tagName":"p"},{"type":"text","content":"Defence will participate in BIO-Europe Spring (March 23-26, Lisbon, Portugal), the premier global partnering event for the life sciences industry. At BIO-Europe, the Company will prioritize discussions with biopharmaceutical partners seeking to collaborate on enhancing the intracellular delivery and efficacy of their ADC programs using Accum®.","length":345,"tagName":"p"},{"type":"text","content":"DCAT Week: Advancing Biomanufacturing Capabilities","length":50,"tagName":"p"},{"type":"text","content":"Defence will also attend DCAT Week (March 23-26, New York), where the Company will focus on strengthening its manufacturing strategy. During DCAT, Defence plans to meet with contract research and manufacturing partners to advance the robust and high-quality biomanufacturing of Accum®, a key operational objective for the Company. Defence has recently become a member of the Drug, Chemical & Associated Technologies Association ("DCAT"), reinforcing its commitment to ensuring the well-characterized, quality-controlled, and commercially ready production of Accum®.","length":579,"tagName":"p"},{"type":"text","content":"Expanding U.S. Presence and Investor Engagement","length":47,"tagName":"p"},{"type":"text","content":"In parallel, Defence will participate in the South Florida Life Sciences Showcase (March 24, Miami) and FII PRIORITY Miami (March 25-27), supporting the Company's ongoing inv...